ClinicalTrials.gg
RecruitingNCT06960161Updated May 8, 2026

Exploring the Use of Phototherapy to Improve CPAP Compliance

A Phase 1 interventional study of Phototherapy in Obstructive Sleep Apnea, sponsored by University of Alberta. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by University of Alberta · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jan 2024, registered Apr 2025).
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Sleep Apnea, Obstructive by University of Alberta — 5 open to participants now, 5 under way, none of them phase 3. Sleep Apnea, Obstructive · University of Alberta.

Started
2024
with 1 other
Phase 1
2 of 10
2 open now
Registered
8th of 10
by date

Among the 10 studies in Sleep Apnea, Obstructive by University of Alberta, this one is one of 2 that started in 2024, is one of 2 in phase 1, and was the 8th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

5 of the 10 studies in Sleep Apnea, Obstructive by University of Alberta are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Sleep Apnea, Obstructive by University of Alberta, or all of them as a file.
02

Study summary

Photobiomodulation (PBM) is a type of light therapy like lasers and LEDs. PBM was previously known by different terms like "low-level laser therapy" (LLLT) or "photobiostimulation." LLLT, despite its name, can also have effects beyond biomodulation, including thermal effects useful in medical imaging and therapy.

PBM works by interacting with our biological systems, and its clinical benefits depend on factors like light wavelength, and energy output.

PBM has various clinical applications, such as wound healing, pain management, and treatment in sports injuries. It's also used as an adjunct to surgery, reducing risks and improving outcomes in areas like wound healing and inflammation. In oral medicine, PBM is applied to conditions like oral aphthous ulcers and is well-recognized for its positive effects in treatment of oral inflammation for oncology patients.

Recent studies indicate that PBM, when administered by trained professionals, can improve sleep quality and reduce snoring/SDB in adults. There's potential for its use in treating obstructive sleep apnea (OSA), showing effectiveness similar to dental sleep appliances but with fewer side effects. This effect seems to be from stabilization of the upper airway. Combining PBM with other therapies, like dental sleep appliances, has shown promise in enhancing effectiveness.

However, whether the effect of PBM in stabilizing the upper airway to reduce snoring/SDB can be used in combination with continuous positive airway pressure (CPAP) to decrease CPAP pressures and improve patient compliance has not been explored.

Read the detailed description

Photobiomodulation (PBM) is a type of light therapy like lasers and LEDs. PBM was previously known by different terms like "low-level laser therapy" (LLLT) or "photobiostimulation." LLLT, despite its name, can also have effects beyond biomodulation, including thermal effects useful in medical imaging and therapy.

PBM works by interacting with our biological systems, and its clinical benefits depend on factors like light wavelength, and energy output.

PBM has various clinical applications, such as wound healing, pain management, and treatment in sports injuries. It's also used as an adjunct to surgery, reducing risks and improving outcomes in areas like wound healing and inflammation. In oral medicine, PBM is applied to conditions like oral aphthous ulcers and is well-recognized for its positive effects in treatment of oral inflammation for oncology patients.

Recent studies indicate that PBM, when administered by trained professionals, can improve sleep quality and reduce snoring/SDB in adults. There's potential for its use in treating obstructive sleep apnea (OSA), showing effectiveness similar to dental sleep appliances but with fewer side effects. This effect seems to be from stabilization of the upper airway. Combining PBM with other therapies, like dental sleep appliances, has shown promise in enhancing effectiveness.

However, whether the effect of PBM in stabilizing the upper airway to reduce snoring/SDB can be used in combination with continuous positive airway pressure (CPAP) to decrease CPAP pressures and improve patient compliance has not been explored.

03

Conditions studied

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • using CPAP
  • problems with CPAP tolerance/snoring

Exclusion criteria

Exclusion Criteria:

  • not using CPAP
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Interventions

  • DevicePhototherapy

    Phototherapy

06

What researchers measure

Primary outcomes

  1. CPAP pressure

    CPAP pressure

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2030, 83 months after the start.

Of 27 phase 1 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 44. This study's planned 83 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 7, 2025
StartActual
Jan 5, 2024
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06960161
Responsible party
Sponsor
First posted
May 7, 2025
Start date
Jan 5, 2024
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
May 8, 2026

Study contacts

Enoch Ng
Contact
enoch@ualberta.ca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion